With an increasing number of projects entering the pipeline both clinically and pre-clinically aimed at targeting "undruggable" transcription factors, the industry is ready to develop further insight into the commercialization of TF-based therapeutics within oncology and other disease settings. Harnessing functional biology and translational research to evaluate which strategies - including PPI inhibitors, TRAFTACs and RNA modulators - are most effective in targeting these elusive proteins is crucial to stay ahead of the curve!The Transcription Factor Drug Development Congress is one of a kind!For the second year running, we will bring together leading industry players within large pharma and biotech, along with expert academics in transcriptomics, epigenetics, and oncology drug discovery. With a year of virtual events under our belt, our streamlined platform will provide an open forum to facilitate the sharing of in vitro and in vivo data, as well as build a deeper understanding of transcriptional machinery to make the ‘undruggable’ druggable. Use 1-2-1 meetings, interactive roundtables and discussions as well as networking roulette to hear strategies that will help you overcome the structural biology, pharmacology, and chemical obstacles in the design and development of TF-based therapeutics. Here’s a sneak peek at our 2021 offering:Understand how chromatin remodelling machinery is involved in DNA binding of the transcriptome and use this to inform targeted epigenetic therapiesAnalyse hot-off-the-press approaches to targeting myc, STAT, p53 and more including TRAFTACs, protein degraders, CPPs and PPI inhibitorsLearn how to build effective collaborations between academic labs, biotech and pharma and get insight into transcriptome and epigenetic focused tool development